Alopecia

Posts

Alopecia

Alopecia Market Projected to be 11.8 Billion By 2024

/in /by

Alopecia Market Projected to be Worth $11.8 Billion By 2024

The global alopecia market was valued at over USD 7.3 billion in 2015. Key factors attributing to the growth of the alopecia market include the increasing prevalence of various chronic diseases such as arthritis, depression, PCOS, diabetes mellitus, hypertension, and cancer, easy access to scalp treatment, and the research & development of several alopecia treatment products.

Changing lifestyles of people such as the increasing consumption of alcohol, tobacco, and other associated products, increasing stress levels, and the rapidly increasing geriatric population are expected to boost the alopecia treatment market during the forecast period.

The increasing disposable incomes coupled with the rising celebrity culture and the increased emphasis being laid on aesthetic appearance; these factors altogether are contributing to the alopecia treatment market growth.

Additionally, technological advancements on the ground of product development of novel therapeutic options are some other important drivers of the alopecia market.

The increasing level of air and water pollution and genetic disorders are also leading to the increasing prevalence of hair loss.

The introduction of robust and rapid acting JAK drugs approved by the FDA, the development of methods to stimulate hair growth using human pluripotent stem cells, the development of PRP treatment, the introduction of a new drug, SM04554 which specifically stimulates hair growth in men are some of the recent technological trends in the alopecia treatment market.

North America Alopecia Treatment Market Estimates and Forecasts, by Treatment Type, 2013 – 2024 (USD Million)

Alopecia Market

Treatment Insights

Key treatments for alopecia include oral treatments, topical treatments, and others. In 2015, topical treatment held the majority of the share in alopecia treatment market accounting for over USD 1.0billion in 2015.

Topical treatment generally includes topical corticosteroids, which are available in the form of lotions, gels, and liquids.

The large share of topical treatments is attributed to the high absorbability and non-invasive nature of these treatments, which are the highest impact rendering drivers of this market. However, oral treatments are expected to witness high growth over the forecast period. The two major brands of the alopecia products are Rogaine and Propecia.

Some other brands include Viviscal, Kirkland, Phyto, Amplixin, Ultrax, Proscar, and others. Propecia is used widely since it is found to be more effective in stimulating the growth of damaged hair follicles and is approved by the U.S. FDA. Additionally, it is available in two forms namely liquid and foam, thus it is easy to apply and has minimal side effects.

Gender Insights

Alopecia is most common in men than in women. In the U.S. about 35 million men and 21 million females suffer from hair loss. While in China there are about 21% of males and 6% of females suffering from hair loss. More than 95% of men suffer from androgenetic alopecia.

The major underlying reason is the growing male geriatric population and the smoking habits of men. However, low awareness levels amongst the male population are one of the key factors for the large share of women population in the alopecia treatment market.

In women Polycystic Ovary Syndrome (PCOS) is frequent and it causes hormonal imbalance which leads to androgenetic alopecia. Traction alopecia is also commonly encountered in women due to the increased stress on hair follicles created by certain hairstyles.

In 2015, the alopecia therapeutics in women accounted for over USD 1,370 million and is expected to continue its dominance over the forecast period. High awareness amongst women population pertaining to the hair treatments are the key factors accounting for the large share of the women population seeking therapeutics for alopecia. Alopecia Areata and Telogen Effluvium alopecia are other common types of alopecia found in both men as well as women.

Regional Insights

Key regional markets included in the alopecia treatment market are North America, Asia Pacific, Europe, Latin America, and MEA. In 2015, North America accounted for the majority of the market share and was the highest revenue generating region with the revenue of over USD 2,480 million.

The presence of technologically advanced healthcare infrastructure, high disposable income, and the availability of novel therapeutic options pertaining to the alopecia treatments are few factors contributing to the high market share of the region. Additionally, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high impact drivers for the North America Alopecia therapeutics market.

However, Asia Pacific is expected to grow at a lucrative CAGR of 5.3% over the coming eight years. The large population suffering from alopecia and the rising awareness levels pertaining to the available therapeutic options is one of the key factors for the region’s high growth rate. The economic development coupled with the constantly rising disposable income in countries such as China, India, and Singapore will present high growth opportunities. The recent innovations and technological trends in alopecia treatment, the increasing healthcare expenditures, and the augmented healthcare facilities are expected to boost the alopecia treatment market.

Competitive Market Share Insights

The key players operating in the alopecia treatment market includes Cipla, Merck & Co., Johnson & Johnson, Lifes2good, Dr. Reddy’s Laboratories, Sun Pharma, Kirkland Signature, Alpecin, Vitabiotics, and Phyto Ales Group.

The increasing research and development efforts to enhance alopecia treatments, the strategic initiatives taken by the key players of the market, and the FDA approval obtained for certain products are the major competitive strategies paving towards the alopecia market expansion. In April 2016, Johnson & Johnson declared the launch of a new global healthcare initiative to provide healthcare solutions, in Africa. In January 2016, Cipla announced that they have 200 drugs under development, of which 50 drugs have the potential to generate USD 30 billion.

Source

alopecia trial

New Treatment for Alopecia Areata

/in /by

Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata

Concert Pharmaceuticals, Inc today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for which there are currently no approved treatments.

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, which is commercially available under the name Jakafi® in the United States for the treatment of myelofibrosis and polycythemia vera.

Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease.

Concert’s Phase 1 program will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of single- and multiple-ascending doses of CTP-543 in healthy volunteers.

“Alopecia areata is a disease that can have devastating effects on patients but which currently lacks approved and effective therapies.

We are pleased to broaden Concert’s pipeline of clinical drug candidates with the advancement of CTP-543 into clinical testing. CTP-543 is another example of how we have applied our novel deuterium platform to create medicines that represent new treatment options,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.

“Recent advances in our understanding of alopecia areata biology, combined with patient data from several investigator-initiated studies, give us confidence that CTP-543 has potential to be an effective treatment.

We hope to move this program quickly through Phase 1 evaluation in order to initiate efficacy studies in patients with alopecia areata next year.”

The Phase 1 program is expected to enroll approximately 80 healthy volunteers. Dosing has been initiated to assess the safety, tolerability, and pharmacokinetics of single-ascending oral doses of CTP-543 in a double-blind trial compared to placebo.

Following successful completion of the first part of the Phase 1 trial, Concert will assess CTP-543 dosed orally once-daily or twice-daily for seven consecutive days in a double-blind, placebo-controlled, multiple-ascending dose trial. Pharmacodynamics of CTP-543 will also be assessed after a single dose and after 7 days of dosing in the multiple-ascending dose trial.

The Company expects to report top-line data upon completion of the multiple-dose Phase 1 program in the fourth quarter of 2016 and initiate a Phase 2 efficacy study in early 2017.

Additional information is available at www.clinicaltrials.gov.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men.

Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative (PFDDI) meeting during fiscal year 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy.

The Company is developing a broad pipeline targeting genetic diseases, autoimmune disorders, CNS disorders and inflammatory diseases, among others.

For more information, please visit www.concertpharma.com.

References
1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Source

market research alopecia

Alopecia Clinical Review

/in /by

Alopecia Clinical Review, Market Growth, Segment, Trends and Forecast 2016 – 2020

“Alopecia Worldwide 2016 Clinical Trials Review, H2″ includes an complete overview of Alopecia scenario.

This Alopecia report provides data relating on Alopecia clinical trials scenario across globe.

Alopecia report also includes an review of trial numbers and also their ( Alopecia ) average enrollment in uppermost countries which are conducted globaly on Alopecia scenario.

This Alopecia report also covers disease clinical trials by country (G7 & E7), Alopecia trial status, sponsor type, region and end points status on Alopecia scenario.

GlobalData’s clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2016″ provides an overview of Alopecia clinical trials scenario.

This report provides top line data relating to the clinical trials on Alopecia.

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database.

Report Alopecia also Includes prominent drugs for in-progress trials – on Alopecia scenario.(Note: based on number of ongoing trials).

Scope of Alopecia Report:-

1. This report ( Alopecia Worldwide 2016 Clinical Trials ) includes a snapshot of global clinical trials landscape on Alopecia scenario.

2. Report on Alopecia also provides top level data related to the worldwide clinical trials by country (G7 & E7), trial status, sponsor type, region as well as end points status on Alopecia scenario.

3. Alopecia Global 2016 Clinical Trials – Report reviews top companies involved in Alopecia and provides enlists all trials (Trial title, Phase, and Status) pertaining to the company on Alopecia scenario.

4. This report provides all the unaccomplished trials on Alopecia scenario with reason for unaccomplishment on Alopecia .

5. Report on Alopecia provides enrollment trends for the past five years – on Alopecia scenario.

6. Report provides latest news relted to Alopecia for the past three months.

7. Report Also Includes Top news in past 3 months on Alopecia clinical trials review scenario.

Reasons to buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

 

CTP-543 alopecia

CTP-543 for Treatment of Alopecia Areata

/in /by

Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced its next product candidate, CTP-543, for the treatment of alopecia areata. Alopecia areata is an autoimmune disease characterized by patchy or widespread hair loss, for which there is significant unmet medical need and currently no FDA-approved treatment.

CTP-543 is a deuterium-modified analog of ruxolitinib, which selectively inhibits Janus kinases 1 and 2, known as JAK1 and JAK2.

Ruxolitinib is commercially available under the name Jakafi® in the United States for the treatment of myelofibrosis and polycythemia vera.

Concert expects to initiate Phase 1 clinical evaluation of CTP-543 in the second quarter of 2016 with efficacy studies commencing in 2017.

Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease.

Preclinical studies conducted by the Company demonstrated that CTP-543 retains ruxolitinib’s selective JAK 1/2 inhibition profile and shows improved metabolic stability.

“We are very excited about the potential of CTP-543 to greatly enhance patient care for individuals with alopecia areata. CTP-543 represents an opportunity to address an important disease where new and effective treatment options are needed,” said Roger Tung, Ph.D.,

President and Chief Executive Officer of Concert Pharmaceuticals. “Based on demonstrated clinical activity of ruxolitinib in alopecia areata, CTP-543 has the potential to become an important first-in-class oral medicine to treat a devastating condition affecting millions of people in the U.S.”

Recently, the U.S. Patent and Trademark Office issued U.S. Patent No. 9,249,149 that claims CTP-543 as a novel composition of matter.

“CTP-543 is a prime example of the application of our deuterium platform to create proprietary new medicines which enhance and extend the utility of known molecules into new therapeutic areas.

We believe we have developed a valuable, potentially first-in-class new drug candidate for an important unmet medical need and look forward to advancing CTP-543 into clinical evaluation shortly,” said Dr. Tung.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

According to MD Anderson, nearly 2% of people in the United States, including both adults and children, suffer from alopecia areata.

There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative (PFDDI) meeting during fiscal year 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Conference Call and Webcast

The Company will host a conference call and webcast tomorrow, May 5, 2016 at 8:30 a.m. EDT to discuss first quarter financial results and the CTP-543 program.

A live webcast may be accessed in the Investors section of the company’s website at www.concertpharma.com.

Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs.

This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy.

The Company is developing a broad pipeline targeting genetic diseases, autoimmune disorders, CNS disorders and inflammatory diseases, among others.

For more information, please visit www.concertpharma.com.

Source

Simvastatin/Ezetimibe Not Beneficial in Alopecia Areata

Simvastatin/Ezetimibe Not Beneficial in Alopecia Areata

/in /by

Simvastatin/Ezetimibe Not Beneficial in Alopecia Areata

Simvastatin/ezetimibe does not appear to be beneficial for severe alopecia areata (AA) in a sample of 20 patients, according to a letter to the editor published in the May issue of the Journal of the American Academy of Dermatology.

Camilla Loi, M.D., from the University of Bologna in Italy, and colleagues present the results of a prospective study with simvastatin/ezetimibe in 20 patients older than 18 years with AA totalis/universalis or involvement of the scalp >70 percent, who had previously undergone one or more treatments.

For six months, patients were given simvastatin/ezetimibe 40 mg/10 mg daily.

Patients were evaluated every eight weeks and underwent global photography and blood tests together with assessment of the tolerability of the drugs.

The researchers found that 85 percent of patients had completed the study at the end of the six-month treatment period.

Eighty-two percent of patients (14 of 17) had no hair regrowth; 12 and 6 percent had a transient diffuse hair regrowth followed by total hair loss in one month during the treatment period and a patchy hair regrowth of pigmented hair, respectively.

Three patients had side effects, including mild headache or muscle cramps, which did not interrupt treatment.

“In conclusion, we did not obtain any result with simvastatin/ezetimibe therapy in severe AA,” the authors write.

“More studies with a control group, a higher number of patients, and a longer duration of therapy are necessary to verify the real role of simvastatin/ ezetimibe in the treatment of AA.”

Source

alopecia report

Alopecia Treatment Market

/in /by

Alopecia (Hair Loss)Treatment Market: Global Industry Analysis and Forecast 2016 – 2022

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. Sedentary lifestyle, and unhealthy diets is leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic disease like arthritis, cancer, hypertension, depression also leads to hair loss especially among middle aged population.

According to American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

For the treatment of alopecia, U.S. FDA proved two drugs – Minoxidil, to treat hypertension and finasteride (Propecia) to treat benign prostate hyperplasia (BPH).

American Hair Loss Association recommends the use of minoxidil in patients who have not responded to finasteride treatment. Prevalence rate of alopecia is high among working age population.

Treatment seeking rate for alopecial is more prevalent in developed regions as compared to that in developing regions, however, over the past few years, demand for alopecia treatment has increased dramatically in developing regions such as China and India owing to increase in healthcare expenditure and improved healthcare infrastructure facilities.

In China, 6 percent females and 21 percent of males suffer from hormone driven hair loss.

Changing lifestyle along with increase in stress level among working class population is expected to boost the demand for treatment of hair loss globally.

Furthermore, rise in geriatrics population along with high demand for surgical hair transplant is expected to drive the alopecia treatment market.

Increasing consumer disposable incomes and health awareness, emphasis to look good, and technological advancement in hair treatment medical devices are some other key drivers for this market.

Since accessibility for scalp treatment is easily accessible and available, the demand for alopecia treatment has increased.

Though the market is expected to witness healthy growth during the forecast period, high cost of the medications and possible side effects/allergic reactions are acting as key barrier for alopecia market.

Alopecia Treatment Market is broadly classified on the basis of the following segments –

Alopecia Treatment Market by Product:

  • Vitamins and Supplements
  • Shampoos and Conditioners
  • Others (Serums, gels and oils)

Alopecia Treatment Market by Gender:

  • Men
  • Women
  • Children

Alopecia Treatment Market by End User:

  • Homecare Settings
  • Dermatology Clinics
  • Others (Salons)

The alopecia treatment market has grown substantially at a healthy CAGR due to changing lifestyle and greater emphasis on outward appearance to look good.

With rapid technological advancement and innovation, alopecia treatment market is expected to grow globally.

North America is the largest market for alopecia treatment while Asia Pacific is expected to be the fastest growing market during the forecast period.

The alopecia treatment market is expected to register a significant CAGR during the forecast period.

Depending on geographic regions, alopecia treatment is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America, followed by Europe, is expected to dominate the alopecia treatment market throughout the forecast period.

Asia Pacific excluding Japan is poised to witness fastest growth owing to outburst of middle aged population in the region.

Also, the region is witnessing healthy growth in terms of GDP, which in turn is expected to propel growth at healthy digits. Middle East & Africa and Latin America are expected to sluggish growth during the forecast period.

Some of the key market players for alopecia treatment market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson.

The report covers exhaustive analysis on:

  • Alopecia Treatment Market Segments
  • Alopecia Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Alopecia Treatment Market Size & Forecast 2016 to 2022
  • Alopecia Treatment Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Alopecia Treatment Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

About Us:

Persistence Market Research (PMR) is an innovative provider of market research reports and consulting services.

The three PMR pillars of strength that have helped us win clients for years are: Quality Research, Quick Research, and In-depth Research.

PMR’s team of seasoned analysts and consultants are experts in their domain. At PMR, we process complex, exhaustive primary and secondary research data into valuable insight.

Web: http://www.persistencemarketresearch.com

Source

Europe Alopecia Areata Market Highlights 2015

Europe Alopecia Areata Market Highlights 2015

/in /by

Europe Alopecia Areata Market Highlights 2015

Research and Markets has announced the addition of the “Europe Alopecia Areata Market Highlights – 2015” report to their offering.

The research helps executives track competitor drugs sales and market share in Europe alopecia areata market. It supports decision making in R&D to long term marketing strategies.

The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Europe alopecia areata market.

The research includes Europe (Germany, France, Italy, Spain, and UK) alopecia areata market size estimates for 2014, market share forecast for six years to 2020, alopecia areata drugs market share, alopecia areata drugs sales estimates, alopecia areata drugs sales forecast, and alopecia areata late stage pipeline products.

Highlights:

  • Marketed Alopecia Areata Drugs in Europe
  • Europe Alopecia Areata Market Analysis
  • Alopecia Areata Drugs Sales Analysis in Europe
  • Competitive Landscape in Europe Alopecia Areata market
  • Alopecia Areata Late Stage Pipeline
  • Europe Alopecia Areata Market Forecast
  • Alopecia Areata Drugs Sales Forecast in Europe
  • Future Competitive Landscape

Benefits of this Report:

  • Identify drugs marketed in Europe for treating alopecia areata including trade name, molecule name, and company.
  • Find out estimates for Europe alopecia areata market size in 2014, key products and their sales, and how the market and products advanced from 2011. You will benefit from our accurate country and indication level valuation of products and the market.
  • Know the market share of leading alopecia areata brands in Europe, including generics share.
  • Find out pipeline products in clinical trial phase 3 and phase 2 for the treatment of alopecia areata. Our coverage includes molecule, mechanism of action, and the company.
  • Gain insights into how Europe alopecia areata market will advance along with market forecast till 2020.
  • Find out how alopecia areata drugs will be positioned in Europe in 2020, with drug sales forecast and drug market share analysis for both marketed products and pipeline products.

Report Structure:

1. Alopecia Areata – Disease Definition

2. Marketed Alopecia Areata Drugs in Europe

3. Europe Alopecia Areata Market Analysis

4. Competitive Landscape in Europe Alopecia Areata Market

5. Europe Alopecia Areata Market – Future Market Outlook

Source

Samumed-hair loss trial

Samumed Phase II Study For A Potential Treatment Of Alopecia

/in /by

Samumed Announces Increases In Both Hair Count And Hair Density Observed In Its Phase II Study For A Potential Treatment Of Androgenetic Alopecia (AGA)

Samumed, LLC, a leader in tissue regeneration, announced today preliminary analysis of efficacy data from its Phase II AGA trial, in which one of the dosage arms, compared to vehicle, showed statistically significant increases for both objective outcome measures: non-vellus hair count (a primary outcome measures) and hair density (a secondary outcome measures), using the pre-specified statistical model.

Samumed’s investigational drug is a topical solution of its novel small molecule compound SM04554.  The 300-subject, multi-center, randomized (1:1:1), double-blind, vehicle-controlled trial studied the safety, tolerability and efficacy of two different doses of SM04554 in male subjects with AGA between the ages of 18 and 55 with Norwood-Hamilton hair loss classification scales of 4, 5, 5A, 5V, or 6.

The study involved a 90-day once-a-day treatment period and a 45-day post-treatment follow up.

The primary endpoints were the objective quantification by macrophotography of non-vellus hair count, and the subjective assessment of hair quality by subject-completed Men’s Hair Growth Questionnaire.

The findings are consistent with preclinical in vivo animal models, in which SM04554 has been shown to generate new hair follicles and increase hair count.

The safety results from its Phase II study, as well as results from a previously completed Phase I study, were presented at the 9th World Congress for Hair Research (WCHR) in Miami, Florida on November 21, 2015.

As the company previously announced, in the Phase II study, there were no serious adverse events observed in any treated patient, and the incidence of adverse events was similar between treatment and vehicle groups.

“The Phase II safety and efficacy data so far are very promising and support moving this program into pivotal studies.

We are analyzing the efficacy data further and plan to present results of both preclinical and clinical studies at upcoming medical conferences,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed.

ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation.

Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

Source

pharma_report-alopecia

Alopecia Global Clinical Trials Review, H1, 2015

/in /by

 

Recent research into the alopecia global clinical trials review for 2015 examined in new market research report

Clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2015″ provides an overview of Alopecia clinical trials scenario.

This report provides top line data relating to the clinical trials on Alopecia.

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Request For Sample Report Here: http://www.marketresearchstore.com/report/alopecia-global-clinical-trials-review-h1-2015-24536#requestSample

Clinical Trial Reports are generated using proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level.

Kerastem Alopecia

Kerastem Receives Conditional Approval from FDA for Alopecia Trial

/in /by

Kerastem Technologies announce that the Company has received notice of conditional approval from the U.S. FDA Center For Biologics Evaluation and Research (CBER) Office of Cellular, Tissue and Gene Therapies to conduct a clinical trial investigating the safety and feasibility of the Company’s technology for the treatment of female and early male pattern baldness (androgenic alopecia).

The phase II study, known as the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the FDA IDE submission.

The data will be presented in September at the 2015 International Society of Hair Restoration Surgery meeting in Chicago.

STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight (8) centers within the United States.

The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density.

According to Principal Investigator Ken Washenik, MD, PhD, Medical Director–Bosley Medical Group, and Clinical Assistant Professor, Department of Dermatology, New York University School of Medicine, “I have been heavily involved in the care and research of alopecia patients and treatments for over 20 years, including the use of cellular based approaches.

As principal investigator of the STYLE trial, I look forward to evaluating this exciting new approach to the treatment of hair loss.”

The global hair loss market is a $7B cash pay business growing annually at 4.8%. “The hair market has few acceptable solutions for early hair loss, particularly in women,” according to Bradford Conlan, CEO of Kerastem. “STYLE represents a defined clinical pathway in the United States and complements our commercial efforts in Europe and Asia,” added Mr. Conlan.

The Company’s platform technology is CE Mark approved and available for patients with alopecia in Europe. Kerastem is currently engaged in market development with select commercial partners.

For more information on STYLE, visit www.kerastem.com

About Kerastem

Kerastem Technologies is a private company owned by Bimini Technologies, and holds global and exclusive rights to commercialize Cytori Therapeutics, Inc.’s Celution® Technology for alopecia and hair related indications.

The Bimini portfolio of products also includes Puregraft (www.puregraft.com, www.thefatexperts.com) the world’s leading fat grafting technology.

Source